Biotech Values

[DewDiligence]

Late-Stage Products Looking for a Home

Criteria for inclusion:
a) Program has completed phase-2b or later and is non-partnered; AND
b) Company lacks the financial resources to commercialize the product on its own.

Edits: Removed ARNA’s Lorcaserin—now partnered (#msg-51889174);
removed JAV’s Dyloject and Ketamine because HSP completed the acquisition
of JAV (http://finance.yahoo.com/news/Hospira-Announces-Successful-prnews-4157218776.html?x=0&.v=1 ).

 
 Company  Product     Phase   Indication (notes)  
 =======  =======     =====   ==================  
 ARYX     Budiodarone 2b      Atrial Fibrillation       
 ARYX     Tecarfarin  3       VTE prevention (failed initial ph-3)              
 CORT     Corlux      3       Cushing’s Syndrome   
 BPAX     Libigel     3       Female Sexual Desire Disorder    
 HNAB     Marqibo     2b      ALL (ENZN failed acc. approval in NHL)      
 ONCY     Reolysin    3       SCC Head & Neck cancer (ph-3 SPA) 	     
 OREX     Contrave    NDA     Obesity         
 OXGN     Zybrestat   3       Anaplastic thyroid cancer         
 MNKD     Afrezza     BLA     Diabetes (CRL rec’d 3/15/10)         
 Pharming Rhucin      apprvd  HAE (approved in Europe; US status unclear)         
 SOMX     Silenor     apprvd  Insomnia (low dose of generic doxepin)         
 SVNT     Krystexxa   BLA     Gout (response to CRL submtd 3/30/10)         
 VVUS     Qnexa       NDA     Obesity

Procedure for Updating Table

1. Copy the text in this post into a word processor.

2. Using a monospace font (e.g. Courier) to facilitate tabular
alignment, make your additions and modifications, inserting
them in the table in alphabetical order. NOTE: use spaces
rather than tab characters.

3. Add a brief note in the “Edits:” line atop the table to
describe your changes.

4. Insert the iHub formatting directives: Put [ pre ] at the
beginning of the table without the surrounding spaces, and
put [ /pre ] at the end of the table without the surrounding
spaces.

5. Post your text as a reply to this message.

Thank you for your cooperation.